Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.87 is 91% above its 5-year average of -21.98, near the high end of its 5-year range (-40.81–-1.87).
82.60% above its 12-month average of -10.75.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.25.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 22 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.87
EARNINGS PER SHARE (EPS) AVG TTM
-10.75
EARNINGS PER SHARE (EPS) AVG 3Y
-23.11
EARNINGS PER SHARE (EPS) AVG 5Y
-21.98
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+82.60%
CURRENT VS 3Y AVG
+91.91%
CURRENT VS 5Y AVG
+91.49%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
IN8bio, Inc.
Market Cap
$13.62M
Earnings Per Share (EPS)
-1.87
TTM Avg
-10.75
3Y Avg
-23.11
5Y Avg
-21.98
Market Cap
$13.72M
Earnings Per Share (EPS)
-29.90
TTM Avg
-175.25
3Y Avg
-40254.86
5Y Avg
-180507.78
Market Cap
$13.78M
Earnings Per Share (EPS)
-11.33
TTM Avg
-17.89
3Y Avg
-30.77
5Y Avg
-41.73
Market Cap
$14.00M
Earnings Per Share (EPS)
-2.11
TTM Avg
-3.38
3Y Avg
-4.90
5Y Avg
-6.31
Market Cap
$13.29M
Earnings Per Share (EPS)
-5.75
TTM Avg
-5.10
3Y Avg
-9.55
5Y Avg
-8.93
Market Cap
$12.95M
Earnings Per Share (EPS)
-1.39
TTM Avg
-1.16
3Y Avg
-1.40
5Y Avg
-1.09
Market Cap
$14.37M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.06M
Earnings Per Share (EPS)
-4.56
TTM Avg
-22.43
3Y Avg
-71.26
5Y Avg
-107.32
Market Cap
$12.63M
Earnings Per Share (EPS)
-0.20
TTM Avg
-0.26
3Y Avg
-0.46
5Y Avg
-0.44
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IN8bio, Inc. (INAB) | $13.62M | -1.87 | -10.75 | -23.11 | -21.98 |
| Vyome Holdings, Inc. (HIND)vs › | $13.72M | -29.90 | -175.25 | -40254.86 | -180507.78 |
| Passage Bio, Inc. (PASG)vs › | $13.78M | -11.33 | -17.89 | -30.77 | -41.73 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.00M | -2.11 | -3.38 | -4.90 | -6.31 |
| Cytosorbents Corporation (CTSO)vs › | $13.29M | -5.75 | -5.10 | -9.55 | -8.93 |
| Optimi Health Corp. (OPTH)vs › | $12.95M | -1.39 | -1.16 | -1.40 | -1.09 |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.37M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $13.06M | -4.56 | -22.43 | -71.26 | -107.32 |
| IRIDEX Corporation (IRIX)vs › | $12.63M | -0.20 | -0.26 | -0.46 | -0.44 |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | -0.79 | -0.84 | -2.55 | -4.78 |
Trailing EPS (TTM)
$-1.87
Forward EPS (Est.)
$-1.11
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -4.44 |
| 2024-12-31 | -17.05 |
| 2023-12-31 | -30.14 |
| 2022-12-31 | -40.81 |
| 2021-12-31 | -23.41 |
| 2020-12-31 | -16.03 |
| 2019-12-31 | -9.16 |
| 2018-12-31 | -3.89 |
